The political language surrounding Germany’s Pharmacy Supply Development Act sounds attractive. It promises to turn the community pharmacy into a modern, easily accessible health hub: more competencies, nationwide pharmaceutical services, year-round vaccinations and even the option of venous blood sampling in a pharmacy consultation environment. When these plans are compared with the commercial reality, however, a difficult contradiction emerges. The model may place acute pressure on many businesses and widen the gap between different types of pharmacy.
The contradiction is already visible in the financial measures. The two-stage increase in the prescription-pack fixed fee to €9.00 in July 2026 and €9.50 in January 2027 may be partly offset by a higher statutory health-insurance discount. Against inflation and rising operating costs, the apparent relief can therefore be considerably smaller than the headline figure suggests. A significant proportion of pharmacies already struggle to earn an adequate return, and a modest remuneration adjustment cannot by itself stop the decline in pharmacy numbers.
At the same time, the services presented as a solution can become a bottleneck in day-to-day staffing and premises. The profession risks splitting into two groups. Large pharmacy groups, shopping-centre locations and high-volume pharmacies may be able to provide separate consultation rooms, modern point-of-care testing equipment and additional staff. Many independent and rural pharmacies, by contrast, already face severe labour shortages and have little spare space or capacity.
If compulsory provision of medically prescribed pharmaceutical services is introduced, this difference in capacity could become more pronounced. Commercial calculations indicate that a service must generate an adequate contribution per minute to cover qualified staff, rooms, preparation, documentation and billing. Complex statutory-insurance administration and fixed reimbursement rates can make some services uneconomic for smaller sites under current conditions.
Tension with the medical profession adds another challenge. Rather than jointly developing integrated care, professional bodies sometimes compete over vaccination, diagnostics and other clinical activities. Although legislation may formally give pharmacists new responsibilities, local pharmacy owners still have to build workable relationships with nearby doctors. Trust and clear division of roles are essential if cross-sector care is to benefit patients.
Pharmacy owners should therefore not assume that publicly financed pharmaceutical services alone will deliver the commercial turnaround. The future of the independent pharmacy lies in an entrepreneurial repositioning that combines patient care with realistic capacity planning, sound processes and a clear local profile. New services can be valuable, but only where reimbursement, staffing, premises and cooperation produce a sustainable model.